Skip to main content

Raise History

Our science has attracted over $30 million from investors, public funds, grants, and incubator investments so far.

Scimar’s operations are supported by our investors. Since launching our seed round in 2018, we’ve attracted over $17.5 million in private investments from more than 99 investors.

In early 2022, we launched our Series A round to build infrastructure, accelerate our research and clinical trials, and support our subsequent market launches of SciMar NuPa Daily: a nutraceutical designed to protect hepatalin production.

  • It’s personal. They know somebody impacted by diabetes and want to be a part of the solution.
  • It’s the science. The data are clear: hepatalin is the missing link.
  • It’s the company. Scimar has a proven track record of success.
  • It’s the approach. We create solutions combining medical and lifestyle interventions.
  • It’s the reasoning. We care about solving the problem, not just selling products.
  • It’s the potential. Our product suite is designed to disrupt a trillion-dollar market.

Public funds, grants, and incubator investments (attracted by Dr. Lautt while working as an academic):$17.3 million
Seed round, 2018:$10.2 million
Bridge round, 2021/22:$4.3 million in preferred convertible shares
Series A round, 2022/23:$5.13 million


*All funds expressed in Canadian dollars